Review





Similar Products

pcmv3 survivin expression plasmid  (Sino Biological)
90
Sino Biological pcmv3 survivin expression plasmid
Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of <t>a</t> <t>pCMV3-survivin</t> expression plasmid <t>(HG10356-UT,</t> Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).
Pcmv3 Survivin Expression Plasmid, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcmv3 survivin expression plasmid/product/Sino Biological
Average 90 stars, based on 1 article reviews
pcmv3 survivin expression plasmid - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human heart cdna  (TaKaRa)
94
TaKaRa human heart cdna
Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of <t>a</t> <t>pCMV3-survivin</t> expression plasmid <t>(HG10356-UT,</t> Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).
Human Heart Cdna, supplied by TaKaRa, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human heart cdna/product/TaKaRa
Average 94 stars, based on 1 article reviews
human heart cdna - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
human gpsm1  (Sino Biological)
94
Sino Biological human gpsm1
Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of <t>a</t> <t>pCMV3-survivin</t> expression plasmid <t>(HG10356-UT,</t> Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).
Human Gpsm1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human gpsm1/product/Sino Biological
Average 94 stars, based on 1 article reviews
human gpsm1 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
pcmv myc ccnd3 cyclin d3 plasmid  (Sino Biological)
94
Sino Biological pcmv myc ccnd3 cyclin d3 plasmid
Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of <t>a</t> <t>pCMV3-survivin</t> expression plasmid <t>(HG10356-UT,</t> Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).
Pcmv Myc Ccnd3 Cyclin D3 Plasmid, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcmv myc ccnd3 cyclin d3 plasmid/product/Sino Biological
Average 94 stars, based on 1 article reviews
pcmv myc ccnd3 cyclin d3 plasmid - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
length wt gfp pfkm construct  (Sino Biological)
94
Sino Biological length wt gfp pfkm construct
Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of <t>a</t> <t>pCMV3-survivin</t> expression plasmid <t>(HG10356-UT,</t> Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).
Length Wt Gfp Pfkm Construct, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/length wt gfp pfkm construct/product/Sino Biological
Average 94 stars, based on 1 article reviews
length wt gfp pfkm construct - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
ahr overexpression plasmid  (Sino Biological)
94
Sino Biological ahr overexpression plasmid
Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of <t>a</t> <t>pCMV3-survivin</t> expression plasmid <t>(HG10356-UT,</t> Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).
Ahr Overexpression Plasmid, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ahr overexpression plasmid/product/Sino Biological
Average 94 stars, based on 1 article reviews
ahr overexpression plasmid - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
hg16923 u  (Sino Biological)
94
Sino Biological hg16923 u
Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of <t>a</t> <t>pCMV3-survivin</t> expression plasmid <t>(HG10356-UT,</t> Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).
Hg16923 U, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hg16923 u/product/Sino Biological
Average 94 stars, based on 1 article reviews
hg16923 u - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
pcmv3 gfpspark plasmids  (Sino Biological)
94
Sino Biological pcmv3 gfpspark plasmids
Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of <t>a</t> <t>pCMV3-survivin</t> expression plasmid <t>(HG10356-UT,</t> Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).
Pcmv3 Gfpspark Plasmids, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcmv3 gfpspark plasmids/product/Sino Biological
Average 94 stars, based on 1 article reviews
pcmv3 gfpspark plasmids - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
mg50714 ut  (Sino Biological)
95
Sino Biological mg50714 ut
Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of <t>a</t> <t>pCMV3-survivin</t> expression plasmid <t>(HG10356-UT,</t> Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).
Mg50714 Ut, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mg50714 ut/product/Sino Biological
Average 95 stars, based on 1 article reviews
mg50714 ut - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
human cd38 gene vector  (Sino Biological)
94
Sino Biological human cd38 gene vector
Expression, characterization, and functional evaluation of rabbit anti-hCD38 polyclonal antibody. (A) Purity and molecular weight of hCD38-His protein detected via SDS–PAGE and Coomassie brilliant blue staining. (B) Purity and molecular weight of rabbit anti-hCD38 pAb analyzed via SDS–PAGE and Coomassie staining. (C) Affinity of rabbit pAb to hCD38-His determined via ELISA (EC 50 = 86.93 ng/mL). (D) Results of indirect anti-human globulin tests in the presence (plus sign) or absence (minus sign) of DARA and pAb are shown. pAb-treated RBCs eliminated DARA-induced pan-agglutination in IAT. (E) Same as panel (D) , using ISA-spiked plasma. The results showed that treatment with pAb eliminated ISA-induced pan-agglutination in IAT. Rabbit pAb, rabbit anti-human <t>CD38</t> polyclonal antibody; DARA, daratumumab; ISA, isatuximab; pAb, polyclonal antibody; RBCs, red blood cells; IAT, indirect antiglobulin test. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination).
Human Cd38 Gene Vector, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd38 gene vector/product/Sino Biological
Average 94 stars, based on 1 article reviews
human cd38 gene vector - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

Image Search Results


Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of a pCMV3-survivin expression plasmid (HG10356-UT, Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).

Journal: Molecular Therapy Oncology

Article Title: Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects

doi: 10.1016/j.omton.2025.201123

Figure Lengend Snippet: Cell death induction by 1H13-survivin/BIRC5-derived peptides targeted to the cytoplasm, mitochondria, or nucleus (A) The sequences added to the 1H13-BIRC5 peptide to target it to the: (1) cytoplasm, (2) mitochondria, or (3) nucleus. The underlined sequence represents the 1H13 peptide; in red, amino acids indicate D-amino acid substitutions. (B) A549 cells were incubated for 90 min with 5 μM FITC-labeled, nucleus-targeted peptide IH13-Nuc, and were also IF-stained with anti--SMAC, anti-IP3R or anti-GM130 antibodies, and stained with DAPI to visualize the mitochondria, ER, Golgi, and nucleus, respectively. Confocal microscope images are shown, with white arrows indicating peptide co-localization with the mitochondria (SMAC). Orange and yellow arrows indicate peptide presence in the nucleus and cytosol, respectively. (C) A549 cells were incubated with the mitochondria- or nucleus-targeted 1H13-BIRC5-derived peptide for 24 h in serum-free medium, followed by a cell proliferation assay using the SRB method. (D and E) Apoptotic cell death as induced in A549 cells following incubation for 24 h with the nucleus-targeted peptide (2/3D-1H13-Nuc) in the presence or absence of the indicated concentrations of the peptides in serum-free medium and subjected to FITC–annexin V/PI staining, followed by a flow cytometry analysis. Representative histograms for control and selected peptide concentration (D) and analysis of early and late apoptotic stages are shown (E). (F and G) Cell death as induced by 2/3D-1H13-Nuc in different cell lines, A549, SH-SY5Y, U-87MG, PC-3, and HUV-EC-C (F) or Jurkat, K562, and KMH2-LC (G) were treated with the indicated concentrations of the peptide for 24 h, then subjected to cell death analysis using propidium iodide (PI) staining and flow cytometry. (H and I) A549 cells were seeded at a density of 2 × 10 5 cells per well in a 12-well plate. After 24 h, the cells were transfected with 2 μg of a pCMV3-survivin expression plasmid (HG10356-UT, Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions. Twenty-four hours post-transfection, the cells were re-seeded at 1 × 10 5 cells per well in a 12-well plate. After another 24 h, the culture medium was replaced with serum-free medium, and the cells were treated with the indicated concentrations of the 2/3D-1H13-Nuc peptide. Survivin overexpression levels were assessed by immunoblotting (H), and cell death was analyzed by propidium iodide (PI) staining followed by FACS analysis (I). Results represent the means ± SEM ( n = 3).

Article Snippet: After 24 h, the cells were transfected with 2 μg of a pCMV3-survivin expression plasmid (HG10356-UT, Sino Biological, China) or with an empty pCMV3 plasmid (control) using JetPrime transfection reagent (Polyplus, France), following the manufacturer’s instructions.

Techniques: Derivative Assay, Sequencing, Incubation, Labeling, Staining, Microscopy, Proliferation Assay, Flow Cytometry, Control, Concentration Assay, Transfection, Expressing, Plasmid Preparation, Over Expression, Western Blot

Expression, characterization, and functional evaluation of rabbit anti-hCD38 polyclonal antibody. (A) Purity and molecular weight of hCD38-His protein detected via SDS–PAGE and Coomassie brilliant blue staining. (B) Purity and molecular weight of rabbit anti-hCD38 pAb analyzed via SDS–PAGE and Coomassie staining. (C) Affinity of rabbit pAb to hCD38-His determined via ELISA (EC 50 = 86.93 ng/mL). (D) Results of indirect anti-human globulin tests in the presence (plus sign) or absence (minus sign) of DARA and pAb are shown. pAb-treated RBCs eliminated DARA-induced pan-agglutination in IAT. (E) Same as panel (D) , using ISA-spiked plasma. The results showed that treatment with pAb eliminated ISA-induced pan-agglutination in IAT. Rabbit pAb, rabbit anti-human CD38 polyclonal antibody; DARA, daratumumab; ISA, isatuximab; pAb, polyclonal antibody; RBCs, red blood cells; IAT, indirect antiglobulin test. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination).

Journal: Frontiers in Immunology

Article Title: A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing

doi: 10.3389/fimmu.2026.1726341

Figure Lengend Snippet: Expression, characterization, and functional evaluation of rabbit anti-hCD38 polyclonal antibody. (A) Purity and molecular weight of hCD38-His protein detected via SDS–PAGE and Coomassie brilliant blue staining. (B) Purity and molecular weight of rabbit anti-hCD38 pAb analyzed via SDS–PAGE and Coomassie staining. (C) Affinity of rabbit pAb to hCD38-His determined via ELISA (EC 50 = 86.93 ng/mL). (D) Results of indirect anti-human globulin tests in the presence (plus sign) or absence (minus sign) of DARA and pAb are shown. pAb-treated RBCs eliminated DARA-induced pan-agglutination in IAT. (E) Same as panel (D) , using ISA-spiked plasma. The results showed that treatment with pAb eliminated ISA-induced pan-agglutination in IAT. Rabbit pAb, rabbit anti-human CD38 polyclonal antibody; DARA, daratumumab; ISA, isatuximab; pAb, polyclonal antibody; RBCs, red blood cells; IAT, indirect antiglobulin test. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination).

Article Snippet: The human CD38 gene vector (Sino Biological, NP_001766 , Cat. HG10818-M, Beijing, China) was amplified using primers listed in .

Techniques: Expressing, Functional Assay, Molecular Weight, SDS Page, Staining, Enzyme-linked Immunosorbent Assay, Agglutination, Clinical Proteomics, Indirect Antiglobulin Test

Preparation, expression, and identification of rabbit anti-human CD38 monoclonal antibodies. (A) Flow cytometric sorting of single B cells; FITC/allophycocyanin (APC) (AF647) double-positive cells in AE gate selected. (B) Purity and molecular weight of rabbit mAbs were detected via staining with Coomassie brilliant blue. (C) ELISA analysis of rabbit mAb binding to hCD38-His. (D) ForteBio Octet determination of the affinities of rabbit mAbs toward hCD38-His. The binding affinity parameter KD was calculated, as reported using ForteBio Data Analysis Software 8.0 (Fremont, CA, USA). (E) Epitope competition assay with DARA by ForteBio. Green, A3; purple, D2. (F) Flow cytometry showing D2 and A3 binding to RBC-expressed CD38. Rabbit mAbs, rabbit anti-human CD38 monoclonal antibodies; DARA, daratumumab; RBC, red blood cell.

Journal: Frontiers in Immunology

Article Title: A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing

doi: 10.3389/fimmu.2026.1726341

Figure Lengend Snippet: Preparation, expression, and identification of rabbit anti-human CD38 monoclonal antibodies. (A) Flow cytometric sorting of single B cells; FITC/allophycocyanin (APC) (AF647) double-positive cells in AE gate selected. (B) Purity and molecular weight of rabbit mAbs were detected via staining with Coomassie brilliant blue. (C) ELISA analysis of rabbit mAb binding to hCD38-His. (D) ForteBio Octet determination of the affinities of rabbit mAbs toward hCD38-His. The binding affinity parameter KD was calculated, as reported using ForteBio Data Analysis Software 8.0 (Fremont, CA, USA). (E) Epitope competition assay with DARA by ForteBio. Green, A3; purple, D2. (F) Flow cytometry showing D2 and A3 binding to RBC-expressed CD38. Rabbit mAbs, rabbit anti-human CD38 monoclonal antibodies; DARA, daratumumab; RBC, red blood cell.

Article Snippet: The human CD38 gene vector (Sino Biological, NP_001766 , Cat. HG10818-M, Beijing, China) was amplified using primers listed in .

Techniques: Expressing, Bioprocessing, Molecular Weight, Staining, Enzyme-linked Immunosorbent Assay, Binding Assay, Software, Competitive Binding Assay, Flow Cytometry

Elimination of DARA- and ISA-induced interference in IAT using rabbit anti-human CD38 monoclonal antibodies and optimization of D2 treatment conditions. Results of indirect anti-human globulin tests in the presence (plus sign) or absence (minus sign) of DARA/ISA and A3/D2 are shown. (A) A3-treated RBCs failed to eliminate DARA-induced interference in IAT. (B, C) D2-treated RBCs eliminated DARA- and ISA-induced pan-agglutination in IAT. (D) Tube 1: negative control. Tube 2: positive control for the DARA interference. Tubes 3–9: per μL of packed RBCs was treated with varying volumes of 1–30 μL D2 (1 mg/mL), and at least 3 μL of 1 mg/mL D2 was required to effectively eliminate DARA interference. (E) Per μL packed RBCs was treated with 3 μL of D2 at room temperature for varying durations (5–15 minutes). Optimization experiments demonstrated that an incubation time of 10 minutes at room temperature was sufficient to eliminate DARA interference in the presence of D2. DARA, daratumumab; ISA, isatuximab; IAT, indirect antiglobulin test; RBCs, red blood cells. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination).

Journal: Frontiers in Immunology

Article Title: A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing

doi: 10.3389/fimmu.2026.1726341

Figure Lengend Snippet: Elimination of DARA- and ISA-induced interference in IAT using rabbit anti-human CD38 monoclonal antibodies and optimization of D2 treatment conditions. Results of indirect anti-human globulin tests in the presence (plus sign) or absence (minus sign) of DARA/ISA and A3/D2 are shown. (A) A3-treated RBCs failed to eliminate DARA-induced interference in IAT. (B, C) D2-treated RBCs eliminated DARA- and ISA-induced pan-agglutination in IAT. (D) Tube 1: negative control. Tube 2: positive control for the DARA interference. Tubes 3–9: per μL of packed RBCs was treated with varying volumes of 1–30 μL D2 (1 mg/mL), and at least 3 μL of 1 mg/mL D2 was required to effectively eliminate DARA interference. (E) Per μL packed RBCs was treated with 3 μL of D2 at room temperature for varying durations (5–15 minutes). Optimization experiments demonstrated that an incubation time of 10 minutes at room temperature was sufficient to eliminate DARA interference in the presence of D2. DARA, daratumumab; ISA, isatuximab; IAT, indirect antiglobulin test; RBCs, red blood cells. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination).

Article Snippet: The human CD38 gene vector (Sino Biological, NP_001766 , Cat. HG10818-M, Beijing, China) was amplified using primers listed in .

Techniques: Bioprocessing, Agglutination, Negative Control, Positive Control, Incubation, Indirect Antiglobulin Test

Elimination of DARA- and ISA-induced interference in IAT using rabbit anti-human CD38 monoclonal antibodies and optimization of D2 treatment conditions. Results of indirect anti-human globulin tests in the presence (plus sign) or absence (minus sign) of DARA/ISA and A3/D2 are shown. (A) A3-treated RBCs failed to eliminate DARA-induced interference in IAT. (B, C) D2-treated RBCs eliminated DARA- and ISA-induced pan-agglutination in IAT. (D) Tube 1: negative control. Tube 2: positive control for the DARA interference. Tubes 3–9: per μL of packed RBCs was treated with varying volumes of 1–30 μL D2 (1 mg/mL), and at least 3 μL of 1 mg/mL D2 was required to effectively eliminate DARA interference. (E) Per μL packed RBCs was treated with 3 μL of D2 at room temperature for varying durations (5–15 minutes). Optimization experiments demonstrated that an incubation time of 10 minutes at room temperature was sufficient to eliminate DARA interference in the presence of D2. DARA, daratumumab; ISA, isatuximab; IAT, indirect antiglobulin test; RBCs, red blood cells. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination).

Journal: Frontiers in Immunology

Article Title: A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing

doi: 10.3389/fimmu.2026.1726341

Figure Lengend Snippet: Elimination of DARA- and ISA-induced interference in IAT using rabbit anti-human CD38 monoclonal antibodies and optimization of D2 treatment conditions. Results of indirect anti-human globulin tests in the presence (plus sign) or absence (minus sign) of DARA/ISA and A3/D2 are shown. (A) A3-treated RBCs failed to eliminate DARA-induced interference in IAT. (B, C) D2-treated RBCs eliminated DARA- and ISA-induced pan-agglutination in IAT. (D) Tube 1: negative control. Tube 2: positive control for the DARA interference. Tubes 3–9: per μL of packed RBCs was treated with varying volumes of 1–30 μL D2 (1 mg/mL), and at least 3 μL of 1 mg/mL D2 was required to effectively eliminate DARA interference. (E) Per μL packed RBCs was treated with 3 μL of D2 at room temperature for varying durations (5–15 minutes). Optimization experiments demonstrated that an incubation time of 10 minutes at room temperature was sufficient to eliminate DARA interference in the presence of D2. DARA, daratumumab; ISA, isatuximab; IAT, indirect antiglobulin test; RBCs, red blood cells. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination).

Article Snippet: The human CD38 gene vector (Sino Biological, NP_001766 , Cat. HG10818-M, Beijing, China) was amplified using primers listed in .

Techniques: Bioprocessing, Agglutination, Negative Control, Positive Control, Incubation, Indirect Antiglobulin Test

Stability of D2 and its efficacy in eliminating therapeutic anti-CD38 antibody interference. Results of indirect anti-human globulin (Coombs’) tests in the presence (plus sign) or absence (minus sign) of daratumumab and D2 are shown. (A) Distribution of anti-CD38 antibody titers (n = 49) and their association with clinical response status. (B) Agglutination scores comparing the efficacy of DTT and D2 in reducing therapeutic anti-CD38 antibody interference. (C) To evaluate the storage stability of D2, it was stored at 4°C, −20°C, and −80°C, and its ability to eliminate DARA interference was assessed via IAT after 1 month (D) , 3 months (E) , or 6 months. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination). DTT, dithiothreitol; DARA, daratumumab; IAT, indirect antiglobulin test.

Journal: Frontiers in Immunology

Article Title: A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing

doi: 10.3389/fimmu.2026.1726341

Figure Lengend Snippet: Stability of D2 and its efficacy in eliminating therapeutic anti-CD38 antibody interference. Results of indirect anti-human globulin (Coombs’) tests in the presence (plus sign) or absence (minus sign) of daratumumab and D2 are shown. (A) Distribution of anti-CD38 antibody titers (n = 49) and their association with clinical response status. (B) Agglutination scores comparing the efficacy of DTT and D2 in reducing therapeutic anti-CD38 antibody interference. (C) To evaluate the storage stability of D2, it was stored at 4°C, −20°C, and −80°C, and its ability to eliminate DARA interference was assessed via IAT after 1 month (D) , 3 months (E) , or 6 months. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination). DTT, dithiothreitol; DARA, daratumumab; IAT, indirect antiglobulin test.

Article Snippet: The human CD38 gene vector (Sino Biological, NP_001766 , Cat. HG10818-M, Beijing, China) was amplified using primers listed in .

Techniques: Agglutination, Indirect Antiglobulin Test